Code of Federal Regulations: Containing a Codification of Documents of General Applicability and Future Effect as of December 31, 1948, with Ancillaries and IndexDivision of the Federal Register, the National Archives, 1998 Special edition of the Federal Register, containing a codification of documents of general applicability and future effect ... with ancillaries. |
No grāmatas satura
1.–5. rezultāts no 99.
13. lappuse
... preparation is a new drug , an application pursuant to section 505 ( b ) of the act is approved for it . ( iv ) The preparation contains not more than 0.325 gram ( 5 grains ) of N- acetyl - p - aminophenol per dosage unit , or if it is ...
... preparation is a new drug , an application pursuant to section 505 ( b ) of the act is approved for it . ( iv ) The preparation contains not more than 0.325 gram ( 5 grains ) of N- acetyl - p - aminophenol per dosage unit , or if it is ...
14. lappuse
... preparation meet their professed standards of iden- tity , strength , quality , and purity . ( iii ) If the preparation is a new drug , an application pursuant to section 505 ( b ) of the act is approved for it . ( iv ) The preparation ...
... preparation meet their professed standards of iden- tity , strength , quality , and purity . ( iii ) If the preparation is a new drug , an application pursuant to section 505 ( b ) of the act is approved for it . ( iv ) The preparation ...
15. lappuse
... preparation is a new drug , an application pursuant to section 505 ( b ) of the act is approved for it . ( iv ) The preparation contains not more than 5 milligrams of dicyclomine hydrochloride per dosage unit , or if it is in liquid ...
... preparation is a new drug , an application pursuant to section 505 ( b ) of the act is approved for it . ( iv ) The preparation contains not more than 5 milligrams of dicyclomine hydrochloride per dosage unit , or if it is in liquid ...
16. lappuse
... preparation meet their professed standards of identity , strength , quality , and purity . ( iii ) If the preparation is a new drug , an application pursuant to section 505 ( b ) of the act is approved for it . ( iv ) The preparation ...
... preparation meet their professed standards of identity , strength , quality , and purity . ( iii ) If the preparation is a new drug , an application pursuant to section 505 ( b ) of the act is approved for it . ( iv ) The preparation ...
17. lappuse
... preparation is a new drug , an application pursuant to section 505 ( b ) of the act is approved for it . ( iv ) The preparation contains not more than 1.0 percent of pramoxine hy- drochloride . ( v ) The preparation is labeled with ...
... preparation is a new drug , an application pursuant to section 505 ( b ) of the act is approved for it . ( iv ) The preparation contains not more than 1.0 percent of pramoxine hy- drochloride . ( v ) The preparation is labeled with ...
Saturs
279 | |
285 | |
290 | |
299 | |
310 | |
331 | |
339 | |
340 | |
223 | |
236 | |
238 | |
239 | |
240 | |
256 | |
257 | |
262 | |
263 | |
265 | |
270 | |
275 | |
351 | |
483 | |
588 | |
593 | |
696 | |
699 | |
761 | |
826 | |
865 | |
890 | |
911 | |
949 | |
Citi izdevumi - Skatīt visu
Bieži izmantoti vārdi un frāzes
abbre abbreviated application abbreviated new drug acid active ingredient adverse drug experience agency amended antibiotic application or abbreviated bacitracin bioavailability bioequivalence cation Center for Drug certification chapter clinical hold clinical investigation conducted control number copy Cosmetic Act digoxin dosage form dose Drug Administration drug application Drug Evaluation drug prod drug product Drug products containing drug substance Evaluation and Research Federal Food Food and Drug graph gredients hearing hydrochloride identified information requirements ap insulin intended inves investigational new drug labeling manufacturer marketing meet ment milligrams milliliters misbranded neomycin notice oral dosage orphan drug OTC drug product package paragraph percent person plication polymyxin proposed protocol recognized as safe reference listed drug request safe and effective safety section 502 Sodium sponsor statement submission Subpart sulfate tained tigational tion tive treatment treatment IND vestigational viated warning